Feb 26, 2016

Posted by in Biotech Stocks | 0 Comments

3 Biotech Stocks Worth Chasing – Ariad Pharmaceuticals Inc. (ARIA), Gilead Sciences Inc. (GILD), Relypsa, Inc. (RLYP)

3 Biotech Stocks Worth Chasing  – Ariad Pharmaceuticals Inc. (ARIA), Gilead Sciences Inc. (GILD), Relypsa, Inc. (RLYP)

 

Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) advanced +1.76% to end the trading session at $5.20. Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) on February 23, 2016, Revenues

  • Net product revenues from sales of Iclusig were $33.3 million for the fourth quarter of 2015, an increase of 56% from the fourth quarter of 2014.
  • U.S. sales of Iclusig were $25.1 million for the fourth quarter, an increase of 48% from the fourth quarter of 2014.
  • European sales of Iclusig were $8.2 million for the fourth quarter, an increase of 86% from the fourth quarter of 2014.
  • Net product revenues from sales of Iclusig for the year ended December 31, 2015 were $112.5 million, an increase of 102% from 2014. In the U.S., net product revenue totaled $85.7 million in 2015, an increase of 114% from 2014, while in the EU, net product revenue totaled $26.8 million in 2015, an increase of 71% from 2014.

Upcoming Investor Meetings

ARIAD management will be participating at the following investor conferences:

  • RBC Capital Markets’ Healthcare Conference, New York City, February 24, 2016
  • Cowen and Company Healthcare Conference, Boston, March 9, 2016
  • Barclays Global Healthcare Conference, Miami, March 17, 2016

Gilead Sciences Inc. (NASDAQ:GILD) rose +0.90% to finish at $90.16. Gilead Sciences Inc. (NASDAQ:GILD) on February 25, 2016, announced that the company’s Marketing Authorization Application (MAA) for tenofovir alafenamide (as fumarate) (TAF) 25 mg – an investigational, once-daily treatment for adults with chronic hepatitis B virus (HBV) infection – has been fully validated and is now under assessment by the European Medicines Agency (EMA).

TAF is a novel, targeted prodrug of tenofovir that has demonstrated high antiviral efficacy similar to Gilead’s Viread® 245 mg of tenofovir disoproxil (as fumarate) (TDF) at one-tenth of the dose. TAF also demonstrated improvements in surrogate laboratory markers of renal and bone safety compared to TDF in clinical trials.

“Chronic hepatitis B infection is a major health concern in Europe, with 14 million people living with the disease and more than 1 million Europeans newly infected with the virus each year,” said Norbert Bischofberger, PhD, Executive Vice President, Research and Development and Chief Scientific Officer, Gilead Sciences. “The validation of this application represents the latest step in our continued efforts to advance the care of people living with progressive liver diseases like HBV.”

Relypsa, Inc. (NASDAQ:RLYP) dropped -15.14% to $14.24. Relypsa, Inc. (NASDAQ:RLYP) on February 03, 2016, announced that on February 18, 2016, announced that on February 16, 2016, the compensation committee of the company’s board of directors granted 7 new employees options to purchase an aggregate of 24,100 shares of the company’s common stock with a per share exercise price of $18.32, the closing trading price on the grant date, and 12,050 restricted stock units. The stock options and restricted stock units were granted pursuant to the Relypsa, Inc. 2014 Employment Commencement Incentive Plan, which was approved by the company’s board of directors in June 2014 under Rule 5635(c)(4) of the Nasdaq Global Select Market for equity grants to induce new employees to enter into employment with the company.

 

 

Comments are closed.